Radiometals in Imaging and Therapy: Highlighting Two Decades of Research
- PMID: 37895931
- PMCID: PMC10610335
- DOI: 10.3390/ph16101460
Radiometals in Imaging and Therapy: Highlighting Two Decades of Research
Abstract
The present article highlights the important progress made in the last two decades in the fields of molecular imaging and radionuclide therapy. Advancements in radiometal-based positron emission tomography, single photon emission computerized tomography, and radionuclide therapy are illustrated in terms of their production routes and ease of radiolabeling. Applications in clinical diagnostic and radionuclide therapy are considered, including human studies under clinical trials; their current stages of clinical translations and findings are summarized. Because the metalloid astatine is used for imaging and radionuclide therapy, it is included in this review. In regard to radionuclide therapy, both beta-minus (β-) and alpha (α)-emitting radionuclides are discussed by highlighting their production routes, targeted radiopharmaceuticals, and current clinical translation stage.
Keywords: imaging; positron emission tomography; radiometals; radionuclide therapy; single photon emission computerized tomography.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.Br J Radiol. 2018 Nov;91(1091):20180074. doi: 10.1259/bjr.20180074. Epub 2018 Jun 15. Br J Radiol. 2018. PMID: 29658792 Free PMC article. Review.
-
Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer.ChemMedChem. 2021 Oct 6;16(19):2909-2941. doi: 10.1002/cmdc.202100135. Epub 2021 May 10. ChemMedChem. 2021. PMID: 33792195 Review.
-
Chemical and radiochemical considerations in radiolabeling with α-emitting radionuclides.Curr Radiopharm. 2011 Jul;4(3):214-47. doi: 10.2174/1874471011104030214. Curr Radiopharm. 2011. PMID: 22201710 Review.
-
Matching chelators to radiometals for radiopharmaceuticals.Chem Soc Rev. 2014 Jan 7;43(1):260-90. doi: 10.1039/c3cs60304k. Epub 2013 Oct 30. Chem Soc Rev. 2014. PMID: 24173525 Review.
-
Cutting edge rare earth radiometals: prospects for cancer theranostics.EJNMMI Radiopharm Chem. 2022 Aug 26;7(1):21. doi: 10.1186/s41181-022-00173-0. EJNMMI Radiopharm Chem. 2022. PMID: 36018527 Free PMC article. Review.
Cited by
-
177Lu-Labeled Iron Oxide Nanoparticles Functionalized with Doxorubicin and Bevacizumab as Nanobrachytherapy Agents against Breast Cancer.Molecules. 2024 Feb 27;29(5):1030. doi: 10.3390/molecules29051030. Molecules. 2024. PMID: 38474542 Free PMC article.
-
Harnessing Terbium Radioisotopes for Clinical Advancements: A Systematic Review.Nucl Med Mol Imaging. 2025 Feb;59(1):50-61. doi: 10.1007/s13139-024-00891-0. Epub 2024 Nov 12. Nucl Med Mol Imaging. 2025. PMID: 39881968 Review.
-
Aspects and prospects of preclinical theranostic radiopharmaceutical development.Theranostics. 2024 Oct 7;14(17):6446-6470. doi: 10.7150/thno.100339. eCollection 2024. Theranostics. 2024. PMID: 39479448 Free PMC article. Review.
-
Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.J Cancer Res Clin Oncol. 2025 Mar 7;151(3):103. doi: 10.1007/s00432-025-06154-5. J Cancer Res Clin Oncol. 2025. PMID: 40055197 Free PMC article.
-
Visualizing the Tumor Microenvironment: Molecular Imaging Probes Target Extracellular Matrix, Vascular Networks, and Immunosuppressive Cells.Pharmaceuticals (Basel). 2024 Dec 10;17(12):1663. doi: 10.3390/ph17121663. Pharmaceuticals (Basel). 2024. PMID: 39770505 Free PMC article. Review.
References
-
- Pusey W.A. Roentgen rays in the treatment of skin diseases and for the removal of hair. J. Cutan. Dis. Incl. Syph. 1900;18:302–318. doi: 10.1001/archderm.1983.01650260070022. - DOI
-
- Jones P.M. Treatment of lupus by x-rays. Phila. Med. J. 1900;5:63–64.
Publication types
LinkOut - more resources
Full Text Sources